BCM
ASND icon

BlueCrest Capital Management’s Ascendis Pharma A/S ASND Stock Holding History

BlueCrest Capital Management’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-6,245
Closed -$226K – 824
2017
Q3 		$226K Buy
+6,245
New +$179K 0.01% 723

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlueCrest Capital Management's ASND Position: Q4 2017 in Review

BlueCrest Capital Management sold out of Ascendis Pharma A/S (ASND) in Q4 2017, closing a stake of 6,245 shares — an estimated $226K sold.

BlueCrest Capital Management first reported a position in ASND in Q3 2017 and held it in 1 quarter. The position peaked at $226K in Q3 2017. 65 funds tracked by Wall St. Rank hold ASND as of Q4 2017.

  • BlueCrest Capital Management reported no remaining Ascendis Pharma A/S position as of Q4 2017 after selling out during the quarter.
  • BlueCrest Capital Management sold 6,245 Ascendis Pharma A/S shares in Q4 2017, an estimated $226K.
  • BlueCrest Capital Management first reported a position in Ascendis Pharma A/S in Q3 2017 and held it in 1 quarter.
  • BlueCrest Capital Management's Ascendis Pharma A/S position peaked at $226K in Q3 2017.
  • 65 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2017.

Based on BlueCrest Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.